Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors.

Immune-modulatory therapies have dramatically improved the survival of patients with metastatic tumors[1,2]. During the development of cancer, the immune system becomes naturally “tolerant” towards cancer cells, which are seen as part of the “self”. This tolerance is maintained by immune checkpoint pathways that down-regulate immune functions, permitting cancer cells to evade immune attacks[3,4]. Monoclonal antibodies (mAb) directed against regulatory immune checkpoi nt molecules that inhibit T-cell activation enhance this anti-tumor immunity[5].

Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: Eleonora De Martin, Jean-Marie Michot, Barbara Papouin, St éphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Teresa Maria Antonini, Audrey Coilly, Salim Laghouati, Caroline Robert, Aurélien Marabelle, Catherine Guettier, Didier Samuel Source Type: research